TransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion
View original at seekingalpha.comTransMedics outlines 20–25% 2026 revenue growth target while advancing OCS programs and European expansion Earnings Call Insights: TransMedics Group, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
TransMedics has huge opportunities ahead but also a few challenges and moving dynamics, with guidance factoring in all factors to be realistic and enable execution
80% confidenceTransMedics is just getting started and has sights focused on new peaks
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceTransMedics has huge opportunities ahead but also faces a few challenges and moving dynamics, which have been factored into guidance
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4
80% confidenceNOP Connect 2.0 showing efficiency in management and billing, though these are early days
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceBy organ, liver contributed $127 million, heart $26 million and lung $2 million in Q4 2025
80% confidenceWe are not seeing competitive dynamic impacting our ability to execute in 2026 and beyond
80% confidenceOCS Liver market share gains represent pure TransMedics execution excellence
80% confidenceMost lung centers were waiting to see FDA approval to start launching into DENOVO program
80% confidenceOperating margins expected to be up to approximately 250 basis points below 2025 full year levels in 2026, primarily reflecting timing and scale of investments
80% confidenceMost lung transplant centers were waiting for FDA approval before launching into DENOVO program
80% confidenceTransMedics continues to expect operating margins to approach 30% by 2028
80% confidenceOUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceTransMedics is not seeing competitive dynamic impacting ability to execute in 2026 and beyond
80% confidenceOperating margin expanded from 8.5% in 2024 to 18% in 2025
80% confidenceTransMedics is not seeing competitive dynamics impacting ability to execute in 2026 and beyond
80% confidenceThe makers of styrofoam box competitor are refusing to randomize their technology against OCS in ENHANCE Part B
80% confidenceOCS Liver reached 36% of U.S. liver transplant volume in 2025, up from 26% in 2024
80% confidenceOUS transplant revenue grew approximately 33% sequentially to $5 million
80% confidenceTransMedics was prepared and expected ENHANCE Part B trial challenges, and will execute Part B hoping for significant success
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceCompany is laser-focused on ensuring successful execution of initiatives throughout 2026
80% confidenceAlmost 50% of incremental 2026 investment is driven by three transitory elements
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% year-over-year growth and approximately 12% sequential growth
80% confidenceGross margin for full year 2025 was 59.9%, up from 59.4% in 2024, reflecting logistics efficiencies and scale benefits
80% confidenceTotal revenue for Q4 2025 was $160.8 million, representing approximately 32% growth year-over-year and approximately 12% sequential growth from Q3 2025
80% confidenceLiver share gains are pure TransMedics execution excellence
80% confidence